Five Data Security Essentials in SaaS
When implementing Software as a Service (SaaS) solutions in Good Practices (GxP) regulated environments, data security and especially integrity are of paramount importance.
C-realize provides software solutions to help pharmaceutical clients improve product development and meet regulatory standards.
You have successfully submitted your enquiry. Someone from our company will respond ASAP

C-realize works as an IT partner for the pharmaceutical, biotechnology, and medical device sectors, providing software development, Cloud computing services, and regulatory compliance advice and solutions. We primarily work with small and medium-sized biopharmaceutical and medical device companies, as well as life science-focused software vendors, to help them digitalise, streamline, and automate their processes.
C-realize can construct digital quality management systems (QMS) that are integrated with Cloud-native technologies, as well as providing computer systems validation and IT infrastructure qualification for FDA Part 11, EMA Annex 11, and other regulatory compliance. Our aim is to help clients transition to Pharma 4.0 while meeting industry standards and complying with regulatory criteria.
C-realize’s core capabilities are in designing, developing, and testing software for the life science industry, as well as computer system validation and secure compliant cloud computing. We focus on the specific business and regulatory demands of the life science market, including patient safety, product quality, and data integrity.
We draw on our abilities to offer four main services:
In addition to our core services, C-realize provides a range of IT services and products based on our skills in agile software development and an awareness of our clients’ specific needs. These include Cloud services and solutions and Cloud-native microservices, as well as an end-to-end QMS software solution that is available with a free open source license.
OpenQMS.net is a lightweight, scalable, Cloud-native Quality Management System that is designed and built to meet biopharmaceutical quality standards such as Good Manufacturing Practice (GMP), FDA Part 11, and EMA Annex 11.
C-realize holds certification in computer validation management by the European Compliance Academy and is a member of the ISPE International Society for Pharmaceutical Engineering. Our products meet all requirements of the life science industry’s IT regulatory and quality standards, including GxP regulations, Part 11 of Title 21 of the Code of Federal Regulations, Electronic Records and Electronic Signatures (21 CFR Part 11), EU GMP Annex 11: Computerised Systems (Annex 11), ISO 9001, and ISO 27001.
C-realize follows its own proprietary software development lifecycle, which is based on good automated manufacturing practice (GAMP).Our QMS product is designed to be lightweight, Cloud-native, and scalable. Based on Microsoft’s .NET framework, it can easily be integrated with Office365, Azure Cloud and other Microsoft technologies. It is also available with a free open-source licence.
C-realize was founded in 2017 by its current CEO Hao Wang, who has long served as a regulatory compliance consultant to various top pharmaceutical companies. The company’s location in Cluj-Napoca, Romania, takes advantage of the area’s status as a recognised technology hub for south-east Europe.
Since its establishment, C-realize has experienced rapid and continuous growth, assisted by its advantages in providing fast responses, a single point of contact, and deep experience in computer systems validation and secure compliant cloud computing for the life science industry.
When implementing Software as a Service (SaaS) solutions in Good Practices (GxP) regulated environments, data security and especially integrity are of paramount importance.
medAspis, a leading pharmtech company, partnered with C-realize to achieve ISO9001 and ISO27001 certifications through an integrated quality management system.
In Part 2 of its 2024 review, C-realize continues to shed light on US Food and Drug Administration (FDA) and European Medicines Agency (EMA) oversight actions.
In 2024, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) took significant compliance efforts to safeguard drug quality and public health. This C-realize series opener highlights some notable inspections and warning letters.
As we continue to reflect on the cybersecurity landscape of 2024, it's evident that this year has been marked by numerous significant data breaches. In this second part of our review, we focus on four major incidents that have had a profound impact on both organisations and individuals.
As we look back at 2024, it’s clear that the cybersecurity landscape has been more challenging than ever. Here, we highlight some of the top breaches of 2024 and the lessons we can learn from them.
Nonconformance management ensures that any deviation from internal procedures, contractual agreements, laws and regulations are identified, addressed and prevented from recurring. It is a fundamental element of continuous improvement and involves several essential steps.
Although many companies understand the importance of the Software Development Lifecycle (SDLC) in producing quality software, they often lack a structured approach for managing their Data Lifecycle. In an era where AI-driven systems rely heavily on data, integrating a secure data lifecycle with the SDLC is crucial for maintaining reliable and trustworthy systems.
In the dynamic world of software development, updates are a constant but they come with their own set of risks. This article explores risk management strategies in software updates.